Replies to post #195231 on Biotech Values

[DewDiligence]

AMGN/AGN submit 351(k) application for Avastin FoB:

http://finance.yahoo.com/news/amgen-allergan-submit-biosimilar-biologics-210000281.html

AGN retained its stake of the AMGN FoB partnership when selling its generic-drug business to TEVA. The AMGN-AGN FoB collaboration was announced in 2011 (#msg-70097496); the company now known as AGN was originally Watson Pharmaceuticals (before several rounds of mergers and acquisitions).

AMGN and AGN are also collaborating on FoBs for Rituxan, Herceptin, and Erbitux, while AMGN is developing FoBs for Humira and Remicade on its own.

[DewDiligence]

AMGN/AGN submit 351(k) application for Herceptin FoB:

https://finance.yahoo.com/news/amgen-allergan-submit-biosimilar-biologics-130000027.html